The Diagnostic Potential of Extracellular Vesicles Derived From the Blood Plasma of Glioblastoma Patients
- PMID: 39477379
- PMCID: PMC11535900
- DOI: 10.21873/invivo.13752
The Diagnostic Potential of Extracellular Vesicles Derived From the Blood Plasma of Glioblastoma Patients
Abstract
Background/aim: Biomarkers for patients suffering from glioblastoma (GBM) are scarce. Extracellular vesicles (EV) are a promising candidate for a potential biomarker. Therefore, EV concentration could be a potential biomarker of tumor burden, volume, and prognosis.
Patients and methods: Large EV (lEV) and small EV (sEV) were isolated from 36 GBM patients' blood plasma by differential centrifugation. Nanoparticle tracking was used to measure EV concentration. Quantitative analysis of tumor volume was performed by evaluating T2/FLAIR relaxation times.
Results: The mean size of lEV was 173.3 nm ± 18.2 nm, while sEV measured 148.3 ± 9.0 nm. Patients with higher lEV concentrations showed a trend towards longer overall survival (36.1 vs. 16.5 months, p=0.08). Regarding inflammatory markers, higher leukocyte count was positively correlated with higher sEV concentration (r2=0.3887, DF 21, p=0.0015). No significant relationship was found between lEV or sEV concentration and tumor volume.
Conclusion: Overall EV concentration in the peripheral blood is not a predictor of tumor volume. sEV concentration is associated with a potential pro-inflammatory metabolism.
Keywords: Extracellular vesicles; biomarker; glioblastoma; liquid biopsy.
Copyright © 2024, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Conflict of interest statement
The Authors declare no conflicts of interest in relation to this study.
Figures
References
-
- Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231–1251. doi: 10.1093/neuonc/noab106. - DOI - PMC - PubMed
-
- Reuss DE, Mamatjan Y, Schrimpf D, Capper D, Hovestadt V, Kratz A, Sahm F, Koelsche C, Korshunov A, Olar A, Hartmann C, Reijneveld JC, Wesseling P, Unterberg A, Platten M, Wick W, Herold-Mende C, Aldape K, von Deimling A. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol. 2015;129(6):867–873. doi: 10.1007/s00401-015-1438-8. - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources